



November 1, 2017

Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition

- Presentations to highlight efficacy, duration of response, and long-term safety results from ongoing Phase 2 studies in myelodysplastic syndromes and myelofibrosis -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia on December 9-12, 2017.

The oral and poster presentations will include efficacy, duration of response, and long-term safety results from the ongoing Phase 2 studies with luspatercept in myelodysplastic syndromes (MDS) and sotatercept in myelofibrosis (MF). The presentations at the conference will include updated information beyond that included in the abstracts available online on the ASH conference website.

Poster presentation

Title: **Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study** (Abstract: 2982)

Session: 637. Myelodysplastic Syndromes-Clinical Studies: Poster II

Date: Sunday, December 10th

Time: 6:00 - 8:00 p.m. EST (Georgia World Congress Center, Bldg A, Lvl 1, Hall A2)

Oral presentation

Title: **Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN-Associated Myelofibrosis (MF) and Anemia)** (Abstract: 255)

Session: 634. Myeloproliferative Syndromes: Clinical: Phase I/II Trials of Novel Agents in MPNs

Date: Saturday, December 9th

Time: 4:30 p.m. EST (Georgia World Congress Center, Bldg C, Lvl 2, C208-C210)

This is an investigator initiated trial sponsored by M.D. Anderson. Acceleron and Celgene currently have no plans to conduct a company-sponsored trial with sotatercept in myelofibrosis.

The luspatercept clinical poster will be available immediately following the presentation at the conference in the "Science" section on Acceleron's website, www.acceleronpharma.com.

Luspatercept and sotatercept are investigational products that are not approved for use in any country. Luspatercept and sotatercept are being developed as part of the global collaboration between Acceleron and Celgene.

About Luspatercept

Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the transforming growth factor-beta superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoiesis stimulating agents (ESAs), which stimulate the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the MEDALIST study) and in patients with beta-thalassemia (the BELIEVE study). For more information, please visit www.clinicaltrials.gov.

About Sotatercept

Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the transforming growth factor-beta superfamily involved in remodeling and regeneration of a variety of different tissues, including the vasculature and fibrosis.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171101006031/en/>

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma

News Provided by Acquire Media